[go: up one dir, main page]

WO2003029251A1 - Novel process for the synthesis of thiazolidinedione derivatives - Google Patents

Novel process for the synthesis of thiazolidinedione derivatives Download PDF

Info

Publication number
WO2003029251A1
WO2003029251A1 PCT/IN2001/000163 IN0100163W WO03029251A1 WO 2003029251 A1 WO2003029251 A1 WO 2003029251A1 IN 0100163 W IN0100163 W IN 0100163W WO 03029251 A1 WO03029251 A1 WO 03029251A1
Authority
WO
WIPO (PCT)
Prior art keywords
formula
compound
synthesis
reaction
reacting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IN2001/000163
Other languages
French (fr)
Inventor
Sandhya Ujire
Madhavan Sridharan
Sambasivam Ganesh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biocon Ltd
Original Assignee
Biocon Ltd
Biocon India Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocon Ltd, Biocon India Ltd filed Critical Biocon Ltd
Priority to PCT/IN2001/000163 priority Critical patent/WO2003029251A1/en
Publication of WO2003029251A1 publication Critical patent/WO2003029251A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • the present invention relates to process of preparing thiazolidinedione derivatives of formula I known for the treatment of non-insulin dependent diabetes.
  • Non-insulin-dependent diabetes mellitus is a metabolic 0 disorder leading to long-term complications and premature atherosclerosis.
  • EP 0 306 228 describes such a procedure for the synthesis of a number of thiazolidinedione derivatives.
  • US patent 5,726,055 describes a process wherein a yeast reductase, R odotorula giutinis the microbial reductase source for the reduction of the benzylidine group to the desired product.
  • WO 99/23095 describes a process using a noble metal mediated reduction for the benzylidine group while, EP 0306 228 discloses a process for the benzylidine group reduction using dissolving metal methods.
  • the present invention details a process for the preparation of compounds of formula I,
  • This invention particularly relates to a process for the preparation of thiazolidinedione derivatives of the general formula L
  • step (i) is carried out in the presence of a mixture of alumina/lithium hydroxide.
  • step (i) is carried in an organic solvent selected from dimethyl formamide, acetonitrile, toluene or xylene.
  • step (ii) is selected from sodium in methanol, magnesium in methanol, NaBH 4 -
  • step (ii) is carried in tetrahydrofuran.
  • Ar is an unsubstituted or substituted heteroaryl
  • X can be either CH or N
  • R can be either H or alkyl n is 1 when X is CH and R is H n is 2 when X is N and R is CH 3 and G is either F or OH

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Compounds of formula (I), which are useful in the treatment of non-insulin dependent diabetes, and wherein Ar is optionally substituted heteroaryl, X is CH or N, R is H or alkyl, and n is 1 or 2, are prepared by reacting compounds of formula (II) with compounds of formula (VI) wherein G is OH or F.

Description

TITLE OF THE INVENTION
Novel Process for tile synthesis of thiazolidinedione derivatives
FIELD OF THE INVENTION
$ The present invention relates to process of preparing thiazolidinedione derivatives of formula I known for the treatment of non-insulin dependent diabetes. BACKGROUND OF THE INVENTION
Non-insulin-dependent diabetes mellitus (NIDDM) is a metabolic 0 disorder leading to long-term complications and premature atherosclerosis.
Compounds of class like, sulfonylureas, biguanides were used for treatment of patients suffering from such disorders. Substituted 5- arylthiazolidinediones demonstrated potent activity towards non-insulin s dependent diabetes. European patent application numbers 0 008 203, 0 139 421, 0 155 845, 0 177 353, 0 193 256, 0 207 581, 0 208420 and 0 306 228 describes a number of thiazolidinedione derivatives which are disclosed as having hypoglycemic and hypolipidaemic activity.
Traditionally the desired alcohol was first alkylated with the aryl o benzaidehyde followed by condensation with thiazolidinedione to give the benzylidine intermediate, which on hydrogenation afforded the desired product. EP 0 306 228 describes such a procedure for the synthesis of a number of thiazolidinedione derivatives.
US patent 5,726,055 describes a process wherein a yeast reductase, R odotorula giutinis the microbial reductase source for the reduction of the benzylidine group to the desired product. WO 99/23095 describes a process using a noble metal mediated reduction for the benzylidine group while, EP 0306 228 discloses a process for the benzylidine group reduction using dissolving metal methods.
The present invention offers a more general procedure for the synthesis of variety of thiazolidinedione derivatives from a common intermediate, namely 5=(4-hydroxyphenyl)benzyl=2,4=thiazolidϊnedione, which can be alkylated with a suitable alcohol to give the desired pharmaceutical intermediate.
SUMMARY OF THE INVENTION
The present invention details a process for the preparation of compounds of formula I,
Formula I where Ar is a substituted or unsubstituted heteroaryl, X is CH or N, R is hydrogen or alkyl group and n is 1 or 2; is prepared by reacting a compound of formula II with a compound of formula VI, where G is F or OH, and Ar, X, R and n are defined with respect to formula I.
Compounds of formula VI are obtained by reacting a compound of formula IV with thiazolidinedione (formula III) as shown in scheme 1 in the presence of alumina/lithium hydroxide or in the presence of a base chosen from β-alanine, piperidine, pyridine and a solvent chosen from toluene, xylene etc to give a intermediate of formula V.
Formula V
Reacting a compound of formula V with magnesium in the presence of iodine in methanol or a reagent chosen from NaBHcCoCfe or MgBH4 or KBH4 or UBH4 in tetrahydrofuran as solvent to give an intermediate of formula VI as shown in the scheme 2 Formula VI
Reacting a compound of formula VI where G = F or OH with a compound of formula II to give a compound of formula I as shown in the scheme 3. DETAILED DESCRIPTION OF THE INVENTION
This invention particularly relates to a process for the preparation of thiazolidinedione derivatives of the general formula L
The process for the synthesis of compounds of formula I (where Ar is an unsubstituted or substituted heteroaryl, X can be either CH or N, R can be either H or alkyl, n is 1 when X is CH and R is H, n is 2 when X is N and R is CH3) comprising of reacting a compound of formula II (where Ar is an unsubstituted or substituted heteroaryl, X can be either CH or N, R can be either H or alkyl, n is 1 when X is CH and R is H, n is 2 when X is N and R is CH3) with a compound of formula VI (where G = F or OH). The process wherein the compound of formula VI (where G = F or
OH) is reacted with a compound of formula Ha to get a compound of formula la.
The process wherein the compound of formula VI (where G = F or OH) is reacted with a compound of formula lib to get a compound of formula lb.
The process wherein the reaction is carried out in the presence the potassium carbonate-dimethyl formamide, sodium hydride-dimethyl formamide or potassium carbonate-dimethyl sulphoxide.
The process wherein the reaction is carried out by using a compound of formula II where the alcoholic hydroxy group is substituted.
The process wherein the compound of formula VI (where G = F or OH) is prepared by: (i) reacting a compound of formula III with a compound of formula IV(where G = F or OH) to give an intermediate of formula V (where G = F or OH) (ii) hydrogenating the intermediate V(where G = F or OH) in to get the compound of formula VI (where G = F or OH).
The process wherein the reaction in step (i) is carried out in the presence of a mixture of alumina/lithium hydroxide.
The process wherein the reaction in step (i) is carried in an organic solvent selected from dimethyl formamide, acetonitrile, toluene or xylene.
The process wherein the hydrogenation agent in step (ii) is selected from sodium in methanol, magnesium in methanol, NaBH4-
C0CI2, MgBH4/ KBH4or LiBH4. The process wherein the hydrogenation in step (ii) is carried in tetrahydrofuran.
The invention is described with the help of the following examples not to be considered as limiting.
Example 1 Synthesis of 4-Hydroxybenzylidine-2,4-thiazolϊdinedione
(Formula V)
To a mixture of lOg of lithium hydroxide and 40g of basic alumina,
25g of 2,4-thiazolidinedione and 29.2 ml of 4-hydroxy benzaidehyde were added followed by 125ml of DMF. The contents were stirred at room temperature over a period of 24h. The reaction mixture was filtered and the alumina cake was washed with ethyl acetate. The combined filtrate was concentrated to remove ethyl acetate and DMF.
The gummy residue was triturated in isopropanol and the solid obtained was filtered and washed thoroughly with isopropanol and dried to give 29g of the title compound in 64% yield. H NMR (DMSO) - 9.8 (s, 1H), 7.4 (d, 2H), 7.2 (s, 1H), 6.9 (d, 2H) Example 2
5 Synthesis of 5-(4-Fluorobenzγlidine)-2,4-thiazGlidinedione (Formula V )
To a mixture of lOg of lithium hydroxide and 40g of basic alumina, 25g of 2,4-thiazolidinedione and 29.2 ml of 4-fluorobenzaldehyde were added followed by 125ml of DMF. The contents were stirred at room o temperature over a period of 24h. The reaction mixture was filtered and the alumina cake was washed with ethyl acetate. The combined filtrate was concentrated to remove ethyl acetate and DMF. The gummy residue was dissolved in isopropanol and the solid obtained was filtered and washed thoroughly with isopropanol and dried to give 27g of the title s compound in 61% yield. *H NMR (DMSO) - 12.2 (s, 1H), 7.8 (s, 1H), 7.65 (m, 2H), 7.4 (m, 2H) Example 3
Synthesis of 5-(4~Hydroxyphenyl)-2,4-thiazolidinedione (Formula VI) o To a solution of 33g of cobalt chloride in 200 ml of water, 4%
NaOH (330mL) was added. The contents were stirred for 45min at RT and 8.8g of DMG dissolved in 100ml of THF was added over a period of 30min. lOg of the compound from example 1 was added and the contents were cooled to 5°C 8g of sodium borohydride was added in 5 portions and the reaction mixture was allowed to stir at 10°C for 24h. 10% charcoal in 50mL of acetone was added and the contents were stirred for lh and the reaction mixture was filtered through celite. The filtrate was acidified with acetic acid until the product precipitates and the resulting solid was filtered and dried to give 7.5g of the compound melting at 154-156°C.
*H NMR (in DMSO) 2.9-3.0 (m, 1H), 3.2-3.3 (m, 1H), 4.8-4.9 (m, 1H),
6.65 (d, 2H), 7.0 (d, 2H), 9.4 (bs, 1H), 12 (bs, 1H) Example 4
Synthesis of 5-(4-Hydroxγphenγ!)-2,4-thiazolϊdinedione
(Formula VI)
To a solution of 5-(4-hydroxybenzylidine)-2,4-thiazolidinedione (5g in 125ml of methanol), magnesium turnings (5g) was added. The reaction mixture was stirred vigorously for 2h at room temperature.
Vigorous effervescence was observed and the temperature of the reaction mixture rose to 65oc. The stirring was continued for 2h. The reaction mixture was diluted with 100ml of water. The solid was filtered and the filtrate was extracted into 500ml of ethyl acetate. The organic layer was washed with water, brine, dried and concentrated to yield 3g of the desired product.
*H NMR (in DMSO) 2.9-3.0 (m, 1H), 3.2-3.3 (m, 1H), 4.8-4.9 (m, 1H),
6.65 (d, 2H), 7.0 (d, 2H), 9.4 (bs, 1H), 12 (bs, 1H)
Example 5 Synthesis of 5-{4-[(5-Ethyl-2-pyridyl)ethoxγ]benzyl}-2,4- thiazolidinedione (Formula la)
To a stirred solution of 2-(5-ethylpyridiyl)ethanol 5g in DMF (50ml) under an atmosphere of argon, sodium hydride was added in portions.
After the vigorous reaction subsided, the compound from example 4 was added and the reaction mixture was refluxed at 90-110°C for 24h. The reaction mixture was cooled to 0-5°C, excess hydride quenched with water, DMF was removed under reduced pressure and the residue was extracted with ethyl acetate. The organic extracts were washed with water, brine and dried. Upon removal of the solvent the title compound was obtained in 62% yield.
Example 6
Synthesis of 5-{4-[2-(N-methyl-N-(2- pyridyI)amino)ethoxy]benzyl}-2,4-thiazolidinedione (Formula lb)
To a stirred solution of 2-(N-methyl-N-(2-pyriylamino)ethanol 5g in DMF (50ml) under an atmosphere of argon, sodium hydride was added in portions. After the vigorous reaction subsided, the compound from example 4 was added and the reaction mixture was refluxed at 90-110°C for 24h. The reaction mixture was cooled to 0-5°C, excess hydride quenched with water, DMF was removed under reduced pressure and the residue was extracted with ethyl acetate. The organic extracts were washed with water, brine and dried. Upon removal of the solvent the title compound was obtained in 54% yield.
Figure imgf000008_0001
Figure imgf000009_0001
Scheme - 1
Figure imgf000009_0002
G = F or OH Scheme - 2
Figure imgf000010_0001
G = F or OH
Scheme - 3
Figure imgf000010_0002
Where, Ar is an unsubstituted or substituted heteroaryl
X can be either CH or N
R can be either H or alkyl n is 1 when X is CH and R is H n is 2 when X is N and R is CH3 and G is either F or OH

Claims

CLAIMSWe claim:
1. A process for the synthesis of compounds of formula I
Figure imgf000011_0001
Formula I where Ar is an unsubstituted or substituted heteroaryl X can be either CH or N R can be either H or alkyl n is 1 when X is CH and R is H n is 2 when X is N and R is CH3
comprising of reacting a compound of formula II with a compound of formula VI
Figure imgf000011_0002
Formula II Formula VI where G = F or OH where, Ar is an unsubstituted or substituted heteroaryl X can be either CH or N
R can be either H or alkyl n is 1 when X is CH and R is H n is 2 when X is N and R is CH3
2. The process of claim 1, wherein the compound of formula VI, where G = F or OH is reacted with a compound of formula Ha to get a compound of formula la.
Figure imgf000012_0001
Formula Ila Formula la
3. The process of claim 1, wherein the compound of formula VI, where G = F or OH is reacted with a compound of formula lib to get a compound of formula lb.
Figure imgf000012_0002
Formula lib Formula lb
4. The process of claim 1, wherein the reaction is carried out in the presence the potassium carbonate-dimethyl formamide, sodium hydride- dimethyl formamide or potassium carbonate- dimethyl sulphoxide.
5. The process of claim 1, wherein the compound of formula VI is prepared by:
Figure imgf000012_0003
Formula VI where G = F or OH (i) reacting a compound of formula III with a compound of formula IV to give an intermediate of
Figure imgf000013_0001
Formula III Formula IV where G = F or OH
(ii) hydrogenating the intermediate V in to get the compound of formula VI.
Figure imgf000013_0002
Formula V where G = F or OH
6. The process of claim 5, wherein the reaction in step (i) is carried out in the presence of a mixture of alumina/lithium hydroxide.
7. The process of claim 5, wherein the reaction in step (i) is carried in an organic solvent selected from dimethyl formamide, acetonitrile, toluene or xylene.
8. The process of claim 5, wherein the hydrogenation agent in step (ii) is selected from sodium in methanol, magnesium in methanol, NaBH4- CoCI2, MgBH4, KBH4or LiBH4.
9. The process of claim 5, wherein the hydrogenation in step (ii) is carried in tetrahydrofuran.
PCT/IN2001/000163 2001-09-28 2001-09-28 Novel process for the synthesis of thiazolidinedione derivatives Ceased WO2003029251A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/IN2001/000163 WO2003029251A1 (en) 2001-09-28 2001-09-28 Novel process for the synthesis of thiazolidinedione derivatives

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IN2001/000163 WO2003029251A1 (en) 2001-09-28 2001-09-28 Novel process for the synthesis of thiazolidinedione derivatives

Publications (1)

Publication Number Publication Date
WO2003029251A1 true WO2003029251A1 (en) 2003-04-10

Family

ID=11076382

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2001/000163 Ceased WO2003029251A1 (en) 2001-09-28 2001-09-28 Novel process for the synthesis of thiazolidinedione derivatives

Country Status (1)

Country Link
WO (1) WO2003029251A1 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005073227A3 (en) * 2004-01-28 2005-09-22 Usv Ltd A process for the preparation of 5-[4-[2-[n-methyl-n-(2-pyridyl) amino] ethoxy] phenyl methyl] thiazolidine-2, 4-dione maleate
WO2006026934A1 (en) * 2004-09-10 2006-03-16 Zentiva, A.S. Method for the preparation of rosiglitazone
WO2009148195A1 (en) * 2008-06-02 2009-12-10 Daebong Ls, Ltd. 5-(4-hydroxybenzyl)thiazolidine-2,4-dione as intermediate for synthesis of thiazolidinedione based compounds and process for preparing the same
WO2011133442A1 (en) * 2010-04-19 2011-10-27 Metabolic Solutions Development Company Novel synthesis for thiazolidinedione compounds
WO2012021467A1 (en) * 2010-08-10 2012-02-16 Metabolic Solutions Development Company, Llc Synthesis for thiazolidinedione compounds
US8933240B2 (en) 2010-08-10 2015-01-13 Metabolic Solutions Development Company, Llc Synthesis for thiazolidinedione compounds

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5002953A (en) * 1987-09-04 1991-03-26 Beecham Group P.L.C. Novel compounds
GB2324089A (en) * 1997-04-08 1998-10-14 Nitto Chemical Industry Co Ltd Process for the production of a thiazolidine derivative
WO2001012628A1 (en) * 1999-08-17 2001-02-22 Smithkline Beecham P.L.C. Pharmaceutical compositions containing thiazolidinedione derivatives and process for their preparation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5002953A (en) * 1987-09-04 1991-03-26 Beecham Group P.L.C. Novel compounds
GB2324089A (en) * 1997-04-08 1998-10-14 Nitto Chemical Industry Co Ltd Process for the production of a thiazolidine derivative
WO2001012628A1 (en) * 1999-08-17 2001-02-22 Smithkline Beecham P.L.C. Pharmaceutical compositions containing thiazolidinedione derivatives and process for their preparation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GILES R G ET AL: "Regiospecific reduction of 5-benzylidene-2,4-thiazolidinediones and 4-oxo-2-thiazolidinethiones using lithium borohydride in pyridine and tetrahydrofuran", TETRAHEDRON, vol. 56, no. 26, June 2000 (2000-06-01), pages 4531 - 4537, XP004202146 *

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005073227A3 (en) * 2004-01-28 2005-09-22 Usv Ltd A process for the preparation of 5-[4-[2-[n-methyl-n-(2-pyridyl) amino] ethoxy] phenyl methyl] thiazolidine-2, 4-dione maleate
WO2006026934A1 (en) * 2004-09-10 2006-03-16 Zentiva, A.S. Method for the preparation of rosiglitazone
WO2009148195A1 (en) * 2008-06-02 2009-12-10 Daebong Ls, Ltd. 5-(4-hydroxybenzyl)thiazolidine-2,4-dione as intermediate for synthesis of thiazolidinedione based compounds and process for preparing the same
WO2011133442A1 (en) * 2010-04-19 2011-10-27 Metabolic Solutions Development Company Novel synthesis for thiazolidinedione compounds
CN102947269A (en) * 2010-04-19 2013-02-27 新陈代谢解决方案开发公司 Novel synthesis for thiazolidinedione compounds
US8937182B2 (en) 2010-04-19 2015-01-20 Metabolic Solutions Development Company, Llc Synthesis for thiazolidinedione compounds
AU2011242956B2 (en) * 2010-04-19 2015-01-22 Cirius Therapeutics, Inc. Novel synthesis for thiazolidinedione compounds
CN102947269B (en) * 2010-04-19 2015-11-25 新陈代谢解决方案开发公司 A New Synthetic Method of Thiazolidinedione Compounds
WO2012021467A1 (en) * 2010-08-10 2012-02-16 Metabolic Solutions Development Company, Llc Synthesis for thiazolidinedione compounds
US8895748B2 (en) 2010-08-10 2014-11-25 Metabolic Solutions Development Company, Llc Synthesis for thiazolidinedione compounds
US8933240B2 (en) 2010-08-10 2015-01-13 Metabolic Solutions Development Company, Llc Synthesis for thiazolidinedione compounds
US8946435B2 (en) 2010-08-10 2015-02-03 Metabolic Solutions Development Company, Llc Synthesis for thiazolidinedione compounds

Similar Documents

Publication Publication Date Title
CA1277323C (en) Thiazolidinedione derivatives, their production and use
US7863300B2 (en) Process to prepare pioglitazone via several novel intermediates
WO2002051823A1 (en) Process for the preparation of rosiglitazone maleate
CN115448907B (en) Compound for treating peptic ulcer, intermediate and preparation method thereof
EP1756099B1 (en) Synthesis of antidiabetic rosiglitazone derivatives
WO2003029251A1 (en) Novel process for the synthesis of thiazolidinedione derivatives
KR20000071138A (en) Process for the Preparation of Substituted Thiazolidinedione
NZ243651A (en) Process for stereo-selective preparation of chiral thiazolidine-2,4-dione
EP1551831A4 (en) PROCESS FOR PREPARING THE RISPERIDONE
WO2009148195A1 (en) 5-(4-hydroxybenzyl)thiazolidine-2,4-dione as intermediate for synthesis of thiazolidinedione based compounds and process for preparing the same
US6632947B2 (en) Process for the preparation of substituted thiazolidinedione
US8993773B2 (en) Process to prepare pioglitazone via several novel intermediates
US20050043539A1 (en) Process for the preparation of 5-[4-[2-[N-methyl-N-(2-pyridyl) amino] ethoxy] phenyl methyl] thiazolidine-2, 4-dione maleate
US7199240B2 (en) Reductive alkylation of saturated cyclic amines
WO2006126790A1 (en) Processes for preparing 6,7,8-trihydroxy-1-(hydroxymethyl)-3-oxo-2-oxa-4-azabicyclo[3.3.1]nonane
KR100697983B1 (en) New intermediates and method for producing pioglitazone using the same
EP1786808B1 (en) Method for the preparation of rosiglitazone
CN1978428B (en) Method for preparing (3R, %S)-Fluvastatin
JP2967989B2 (en) Tetrahydropyridine derivative and production method thereof
US20070225501A1 (en) Process for the Preparation of Rosiglitazone
EP4071139A1 (en) Crystalline lofexidine hydrochloride
EP2118095B1 (en) A method for the preparation of zolmitriptan
KR101164429B1 (en) Manufacturing method for pioglitazone HCl
JP4447742B2 (en) Method for producing 3-mercapto-1- (1,3-thiazolin-2-yl) azetidine
CN115894338A (en) Method for preparing Ritlecetinib intermediate by coupling chemical enzyme and biological enzyme

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EE ES FI GB GD GE GH GM HU ID IL IN IS JP KE KG KP KR KZ LK LR LS LT LU LV MA MD MG MK MW MX MZ NO NZ PL PT RO RU SD SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZW AM AZ BY KG KZ MD TJ TM AT BE CH CY DE DK ES FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW MR NE SN TD TG US

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP